{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:26:17Z","timestamp":1762028777337,"version":"build-2065373602"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019460","name":"WCM-Q","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032486","name":"Qatar Research, Development and Innovation Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019687","name":"HBKU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.nbd.2025.107116","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:02:13Z","timestamp":1759298533000},"page":"107116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A new serological autoantibody signature associated with multiple sclerosis"],"prefix":"10.1016","volume":"216","author":[{"given":"Houari","family":"Abdesselem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilham","family":"Bensmail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israa E.","family":"Elbashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Anuar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan","family":"Ti-Myen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bermet","family":"Abylova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayaz A.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis N.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2025.107116_bb0005","doi-asserted-by":"crossref","first-page":"13945","DOI":"10.18632\/oncotarget.7359","article-title":"Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort","volume":"7","author":"Adeola","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.nbd.2025.107116_bb0010","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1468-1331.2009.02573.x","article-title":"Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients","volume":"16","author":"Al-Masri","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0015","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/eji.200635883","article-title":"Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigen-specific tolerance","volume":"36","author":"Anderson","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0020","article-title":"Anti-Myxovirus resistance protein-1 immunoglobulin a autoantibody in idiopathic pulmonary fibrosis","volume":"2022","author":"Arai","year":"2022","journal-title":"Can. Respir. J."},{"key":"10.1016\/j.nbd.2025.107116_bb0025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/j.1460-2075.1988.tb02946.x","article-title":"Antiviral state against influenza virus neutralized by microinjection of antibodies to interferon-induced Mx proteins","volume":"7","author":"Arnheiter","year":"1988","journal-title":"EMBO J."},{"key":"10.1016\/j.nbd.2025.107116_bb0030","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0035","first-page":"160","article-title":"Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications","volume":"19","author":"Bjornevik","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-61779-349-3_10","article-title":"Miniaturized, microarray-based assays for chemical proteomic studies of protein function","volume":"800","author":"Blackburn","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2025.107116_bb0045","article-title":"Quantitative, epitope-specific, serological screening of COVID-19 patients using a novel multiplexed array-based immunoassay platform","author":"Blackburn","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.nbd.2025.107116_bb0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.24620","article-title":"Dynamic imaging of individual remyelination profiles in multiple sclerosis","volume":"79","author":"Bodini","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0055","first-page":"26","article-title":"Regulators and conductors of immunity: natural immune system in health and autoimmunity","author":"Borocz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2025.107116_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jneuroim.2009.07.017","article-title":"Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases","volume":"217","author":"Brettschneider","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0065","first-page":"167","article-title":"Structure and function of natural antibodies","volume":"210","author":"Casali","year":"1996","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.cdd.4400633","article-title":"Apoptosis and autoimmunity","volume":"7","author":"Clemens","year":"2000","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.nbd.2025.107116_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.907245","article-title":"The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis","volume":"13","author":"Coerver","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0080","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0952-7915(95)80053-0","article-title":"Natural autoantibodies","volume":"7","author":"Coutinho","year":"1995","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0085","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.autrev.2015.07.014","article-title":"Peripheral blood biomarkers in multiple sclerosis","volume":"14","author":"D\u2019Ambrosio","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.nbd.2025.107116_bb0090","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.52.6.1239","article-title":"Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies","volume":"52","author":"Deisenhammer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.imlet.2015.09.010","article-title":"Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson\u2019s disease","volume":"168","author":"DeMarshall","year":"2015","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.nbd.2025.107116_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.dadm.2016.03.002","article-title":"Detection of Alzheimer\u2019s disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers","volume":"3","author":"DeMarshall","year":"2016","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.nbd.2025.107116_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2017.05.010","article-title":"Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis","volume":"309","author":"DeMarshall","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0110","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1128\/JVI.01753-07","article-title":"Influenza A virus strains differ in sensitivity to the antiviral action of Mx-GTPase","volume":"82","author":"Dittmann","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.nbd.2025.107116_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1256745","article-title":"Profiling the autoantibody repertoire reveals autoantibodies associated with mild cognitive impairment and dementia","volume":"14","author":"Ehtewish","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0125","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/1352458508101944","article-title":"Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event","volume":"15","author":"Freedman","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.nbd.2025.107116_bb0130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.2414848","article-title":"Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity","volume":"230","author":"Fujinami","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.nbd.2025.107116_bb0135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.immuni.2011.07.012","article-title":"Structure of myxovirus resistance protein a reveals intra- and intermolecular domain interactions required for the antiviral function","volume":"35","author":"Gao","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.nbd.2025.107116_bb0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.stemcr.2017.12.014","article-title":"SOX10 single transcription factor-based fast and efficient generation of oligodendrocytes from human pluripotent stem cells","volume":"10","author":"Garcia-Leon","year":"2018","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.nbd.2025.107116_bb0145","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Cell J"},{"key":"10.1016\/j.nbd.2025.107116_bb0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1191\/135248506ms1245oa","article-title":"Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1","volume":"12","author":"Gilli","year":"2006","journal-title":"Mult. Scler."},{"issue":"Suppl. 6","key":"10.1016\/j.nbd.2025.107116_bb0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00415-008-6010-1","article-title":"Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks","volume":"255","author":"Goertsches","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756285610385608","article-title":"Evolving expectations around early management of multiple sclerosis","volume":"3","author":"Gold","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.nbd.2025.107116_bb0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ncl.2020.09.002","article-title":"Advances in the treatment of multiple sclerosis","volume":"39","author":"Goldschmidt","year":"2021","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.nbd.2025.107116_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.03.026","article-title":"Biomarkers of disease activity in multiple sclerosis","volume":"305","author":"Graber","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.nbd.2025.107116_bb0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0404.2007.00872.x","article-title":"Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort","volume":"116","author":"Greeve","year":"2007","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.nbd.2025.107116_bb0180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jir.2010.0038","article-title":"Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis","volume":"31","author":"Grossberg","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.nbd.2025.107116_bb0185","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1034\/j.1600-0854.2002.31003.x","article-title":"Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity","volume":"3","author":"Haller","year":"2002","journal-title":"Traffic"},{"key":"10.1016\/j.nbd.2025.107116_bb0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/jir.2010.0076","article-title":"Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity","volume":"31","author":"Haller","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.nbd.2025.107116_bb0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2007.06.001","article-title":"Interferon, Mx, and viral countermeasures","volume":"18","author":"Haller","year":"2007","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.nbd.2025.107116_bb0200","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.micinf.2007.09.010","article-title":"The Mx GTPase family of interferon-induced antiviral proteins","volume":"9","author":"Haller","year":"2007","journal-title":"Microbes Infect."},{"key":"10.1016\/j.nbd.2025.107116_bb0205","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40291-014-0117-0","article-title":"Biomarkers of therapeutic response in multiple sclerosis: current status","volume":"18","author":"Harris","year":"2014","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.nbd.2025.107116_bb0210","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1212\/WNL.0b013e3181b04c98","article-title":"Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity","volume":"73","author":"Hesse","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0215","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1742-2094-9-140","article-title":"Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance","volume":"9","author":"Hundeshagen","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2025.107116_bb0220","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41586-019-0903-2","article-title":"Altered human oligodendrocyte heterogeneity in multiple sclerosis","volume":"566","author":"Jakel","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2025.107116_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s007050170189","article-title":"Mouse Mx2 protein inhibits hantavirus but not influenza virus replication","volume":"146","author":"Jin","year":"2001","journal-title":"Arch. Virol."},{"key":"10.1016\/j.nbd.2025.107116_bb0230","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/01.wnl.0000171747.59767.5c","article-title":"Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study","volume":"65","author":"Kappos","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrneurol.2011.22","article-title":"Determinants of interferon beta efficacy in patients with multiple sclerosis","volume":"7","author":"Killestein","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0240","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1073\/pnas.96.5.2082","article-title":"Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids","volume":"96","author":"Kochs","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2025.107116_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013066","article-title":"Ontology-based meta-analysis of global collections of high-throughput public data","volume":"5","author":"Kupershmidt","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2025.107116_bb0250","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1128\/JVI.72.2.1516-1522.1998","article-title":"Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins","volume":"72","author":"Landis","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.nbd.2025.107116_bb0255","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2025.107116_bb0260","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1101\/gr.20102","article-title":"Functional diversity of Mx proteins: variations on a theme of host resistance to infection","volume":"12","author":"Lee","year":"2002","journal-title":"Genome Res."},{"key":"10.1016\/j.nbd.2025.107116_bb0265","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jneuroim.2017.07.013","article-title":"Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins","volume":"310","author":"Lindsey","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0270","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ydbio.2006.10.007","article-title":"Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence for reciprocal interactions and dosage-dependent mechanisms","volume":"302","author":"Liu","year":"2007","journal-title":"Dev. Biol."},{"key":"10.1016\/j.nbd.2025.107116_bb0275","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fimmu.2016.00198","article-title":"Role of natural autoantibodies and natural IgM anti-leucocyte autoantibodies in health and disease","volume":"7","author":"Lobo","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0280","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0285","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0295","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1212\/01.wnl.0000304040.29080.7b","article-title":"Predictive markers for response to interferon therapy in patients with multiple sclerosis","volume":"70","author":"Malucchi","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0300","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2015.12.015","article-title":"MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients","volume":"291","author":"Matas","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0305","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.nbd.2025.107116_bb0310","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1590\/S0004-282X2011000400024","article-title":"Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works","volume":"69","author":"Mendes","year":"2011","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.nbd.2025.107116_bb0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1348-0421.2002.tb02673.x","article-title":"Promoted cell death of cells expressing human MxA by influenza virus infection","volume":"46","author":"Mibayashi","year":"2002","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0320","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis","volume":"4","author":"Miller","year":"2005","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0325","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1468-1331.2008.02190.x","article-title":"MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients","volume":"15","author":"Millonig","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203785","article-title":"In vivo conversion of astrocytes into oligodendrocyte lineage cells with transcription factor Sox10; promise for myelin repair in multiple sclerosis","volume":"13","author":"Mokhtarzadeh Khanghahi","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2025.107116_bb0335","doi-asserted-by":"crossref","first-page":"15206","DOI":"10.1074\/jbc.M806324200","article-title":"Inhibition of tumor cell motility by the interferon-inducible GTPase MxA","volume":"284","author":"Mushinski","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2025.107116_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023112","article-title":"Diagnosis of Alzheimer\u2019s disease based on disease-specific autoantibody profiles in human sera","volume":"6","author":"Nagele","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.nbd.2025.107116_bb0345","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0889-857X(03)00110-8","article-title":"Apoptosis and immune responses to self","volume":"30","author":"Navratil","year":"2004","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.nbd.2025.107116_bb0350","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0355","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-0716-1601-7_11","article-title":"Single transcription factor-based differentiation allowing fast and efficient oligodendrocyte generation via SOX10 overexpression","volume":"2352","author":"Neyrinck","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2025.107116_bb0360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0365","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.2174\/138161212802502215","article-title":"An inventory of short term and long term changes in gene expression under interferon beta treatment of relapsing remitting MS patients","volume":"18","author":"Paap","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.nbd.2025.107116_bb0370","first-page":"17","article-title":"MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity","volume":"7","author":"Pachner","year":"2003","journal-title":"Mol. Diagn."},{"key":"10.1016\/j.nbd.2025.107116_bb0375","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/ana.22609","article-title":"Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci","volume":"70","author":"Patsopoulos","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0380","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1128\/jvi.64.7.3370-3375.1990","article-title":"Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein","volume":"64","author":"Pavlovic","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.nbd.2025.107116_bb0385","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1128\/jvi.69.7.4506-4510.1995","article-title":"Enhanced virus resistance of transgenic mice expressing the human MxA protein","volume":"69","author":"Pavlovic","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.nbd.2025.107116_bb0390","first-page":"25","article-title":"Breakdown of self-tolerance and the pathogenesis of autoimmunity","volume":"19","author":"Ring","year":"1999","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.nbd.2025.107116_bb0395","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.nbd.2025.107116_bb0400","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(09)70082-1","article-title":"Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis","volume":"8","author":"Rudick","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0405","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.4161\/cc.6.19.4779","article-title":"Mx1 gene protects mice against the highly lethal human H5N1 influenza virus","volume":"6","author":"Salomon","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.nbd.2025.107116_bb0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1352458514522104","article-title":"To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis","volume":"20","author":"Schirmer","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.nbd.2025.107116_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1203723","article-title":"Auto-immunoproteomics analysis of COVID-19 ICU patients revealed increased levels of autoantibodies related to the male reproductive system","volume":"14","author":"Schmidt","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.nbd.2025.107116_bb0420","first-page":"60","article-title":"The role of glial fibrillary acidic protein as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","author":"Shaygannejad","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.nbd.2025.107116_bb0425","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa1110740","article-title":"Potassium channel KIR4.1 as an immune target in multiple sclerosis","volume":"367","author":"Srivastava","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2025.107116_bb0430","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1101\/gad.215802","article-title":"Terminal differentiation of myelin-forming oligodendrocytes depends on the transcription factor Sox10","volume":"16","author":"Stolt","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.nbd.2025.107116_bb0435","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.08.004","article-title":"Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis","volume":"215","author":"Sundstrom","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.nbd.2025.107116_bb0440","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1286-4579(02)00009-6","article-title":"Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis - a critical review","volume":"4","author":"Swanborg","year":"2002","journal-title":"Microbes Infect."},{"key":"10.1016\/j.nbd.2025.107116_bb0445","first-page":"12","article-title":"Role of viruses in the pathogenesis of multiple sclerosis","author":"Tarlinton","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.nbd.2025.107116_bb0450","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2025.107116_bb0455","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458507077622","article-title":"Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS","volume":"13","author":"Tomassini","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.nbd.2025.107116_bb0460","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1084\/jem.188.9.1725","article-title":"In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis","volume":"188","author":"Ufret-Vincenty","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.nbd.2025.107116_bb0465","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1212\/WNL.58.12.1786","article-title":"Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients","volume":"58","author":"Vallittu","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2025.107116_bb0470","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0404.2007.00968.x","article-title":"MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients","volume":"118","author":"Vallittu","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.nbd.2025.107116_bb0475","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/jir.2010.0085","article-title":"Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis","volume":"30","author":"Vandenbroeck","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.nbd.2025.107116_bb0480","doi-asserted-by":"crossref","first-page":"13445","DOI":"10.1128\/JVI.01682-12","article-title":"Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly","volume":"86","author":"Verhelst","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.nbd.2025.107116_bb0485","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/MMBR.00024-13","article-title":"Mx proteins: antiviral gatekeepers that restrain the uninvited","volume":"77","author":"Verhelst","year":"2013","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.nbd.2025.107116_bb0490","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.nbd.2025.107116_bb0495","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ddr.21169","article-title":"Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE)","volume":"75","author":"Wang","year":"2014","journal-title":"Drug Dev. Res."},{"issue":"Suppl","key":"10.1016\/j.nbd.2025.107116_bb0500","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/ana.410360704","article-title":"Natural history of multiple sclerosis","volume":"36","author":"Weinshenker","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0505","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","article-title":"Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein","volume":"80","author":"Wucherpfennig","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2025.107116_bb0510","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318599121","article-title":"How persistent infection overcomes peripheral tolerance mechanisms to cause T cell-mediated autoimmune disease","volume":"121","author":"Yin","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2025.107116_bb0515","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.expneurol.2018.03.012","article-title":"Molecular pathology of multiple sclerosis lesions reveals a heterogeneous expression pattern of genes involved in oligodendrogliogenesis","volume":"305","author":"Zeis","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2025.107116_bb0520","article-title":"Mechanisms of demyelination and remyelination strategies for multiple sclerosis","volume":"24","author":"Zhao","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2025.107116_bb0525","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.virol.2010.10.008","article-title":"Antiviral activities of ISG20 in positive-strand RNA virus infections","volume":"409","author":"Zhou","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.nbd.2025.107116_bb0530","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.1128\/JVI.00712-11","article-title":"The viral nucleoprotein determines Mx sensitivity of influenza A viruses","volume":"85","author":"Zimmermann","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.nbd.2025.107116_bb0535","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0042-6822(92)90481-4","article-title":"Mouse Mx2 protein inhibits vesicular stomatitis virus but not influenza virus","volume":"187","author":"Zurcher","year":"1992","journal-title":"Virology"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612500333X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612500333X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:22:41Z","timestamp":1762028561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999612500333X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":105,"alternative-id":["S096999612500333X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2025.107116","relation":{},"ISSN":["0969-9961"],"issn-type":[{"type":"print","value":"0969-9961"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new serological autoantibody signature associated with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2025.107116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107116"}}